Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models

Gene Therapy

Volumn 6, Issue 12, 1999, Pages 1988-1994

  Hiroishi, K ^a   Tuting T ^a,b   Tahara, H ^a   Lotze, M T ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer gene therapy; Costimulatory molecule; Dendritic cell; Interferon ; T lymphocyte; Therapeutic model

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; NEOMYCIN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; CARCINOGENICITY; CELL INTERACTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FIBROSARCOMA; GASTROINTESTINAL CARCINOMA; GENE THERAPY; GENETIC TRANSDUCTION; HINDLIMB; IMMUNOCOMPETENT CELL; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD80; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RETROVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; MURINAE;

EID: 17344386195     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301034     Document Type: Article

References (34)

1. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14: 483-486.
2. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48-51.
3. Ferrantini M et al. IFN-α1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-γ-producing TS/A cells. J Immunol 1994; 153: 4604-4615.
4. Kaido T et al. IFN-α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 1995; 60: 221-229.
5. Santodonato L et al. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 1996; 7: 1-10.
6. Coleman M et al. Noviral interferon α gene therapy inhibits growth of established tumors by eliciting a systemic immune response. Hum Gene Ther 1998; 9: 2223-2230.
7. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
8. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 1992; 13: 74-76.
9. Parry RV et al. Evidence that a kinase distinct from protein kinase C and phosphatidylinositol 3-kinase mediates ligation-dependent serine/threonine phosphorylation of the T-lymphocyte co-stimulatory molecule CD28. Biochem J 1997; 15: 249-257.
10. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB1. Proc Natl Acad Sci USA 1990; 87: 5031-5035.
11. Linsley PS et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173: 721-730.
12. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today 1990; 11: 211-216.
13. Harding FA et al. CD28-mediated signaling costimulates murine T cells and prevents induction of anergy in T cell clones. Nature (London) 1992; 356: 607-609.
14. Harding FA, Allison JP. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993; 177: 1791-1796.
15. Gimmi CD et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586-6590.
16. Chen L et al. Co-stimulation of antitumor immunity by the B7 counterreceptor for the lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
17. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
18. Chen L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-532.
19. Zitvogel L et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996; 26: 1335-1341.
20. Hiroishi K, Tüting T, Lotze MT. Interferon-α-expressing tumor cells enhance generation and promote survival of tumor-specific cytotoxic T cells. J Immunol (in press).
21. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999; 189: 521-529.
22. + blood dendritic cells are potent producers of IFN-α in response to HIV-1 infection. J Immunol 1994; 152: 4649-4662.
23. Luft T et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161: 1947-1953.
24. Mayordomo JI et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995; 1: 1297-1302.
25. Zitvogel L et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
26. 2. Proc Natl Acad Sci USA 1988; 85: 6880-6884.
27. Lane HC et al. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 805-811.
28. Parronchi P et al. IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992; 149: 2977-2983.
29. Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon α increases the frequency of interferon γ-producing human CD4+ T cells. J Exp Med 1993; 178: 1655-1663.
30. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103: 161-179.
31. Tan MH, Holyoke ED, Goldrosen MH. Murine colon adenocarcinomas: methods for selective culture in vitro. J Natl Cancer Inst 1976; 56: 871-873.
32. Reeves ME et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996; 56: 5672-5677.
33. Tüting T et al. Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Therapy 1997; 4: 1053-1060.
34. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of hightiter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.